MAP2K7 and Keratoconjunctivitis sicca: Another retrospective case series showed a correlation between different cutaneous and extra-cutaneous adverse events including vitiligo, erythema nodosum, uveitis and keratitis sicca and the treatment outcome upon BRAF inhibitors either administered alone or in combination with MEK inhibitors (12).